Decline of lung function of a LTX patient who rapidly developed severe BOS at our centre. Decline of lung function of a LTX patient who rapidly developed.

Slides:

Advertisements

Similar presentations

Ins and outs of respiratory physiology David Taylor All illustrations and text © The University of Liverpool and David Taylor 2008.

Advertisements

Lung Function Tests Normal and abnormal Prof. J. Hanacek, MD, PhD.

BREATHING By the end of this lesson, I will be able to: Know what tidal volume is. Understand the effects of exercise on breathing.

Normal and abnormal Prof. J. Hanacek, MD, PhD

Pulmonary Function David Zanghi M.S., MBA, ATC/L, CSCS.

An Overview of Pulmonary Function Tests Norah Khathlan M.D. Consultant Pediatric Intensivist 10/2007.

Dr. Taj. What is Spirometry ? It is a measurement of the breathing capacity of the lungs. It is the most basic and frequently performed test of pulmonary.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Pulmonary response in sarcoidosis

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Respiratory Volumes Used to assess a person’s respiratory status

Examples of computerised incentives used in spirometry

Should lung transplantation be performed for patients on mechanical respiratory support? The US experience David P. Mason, MD, Lucy Thuita, MS, Edward.

William G. Flight, Jonathan Shaw, Susan Johnson, A

Mortality Risk and Pulmonary Function in Adults With Cystic Fibrosis at Time of Wait Listing for Lung Transplantation Don Hayes, MD, MS, Stephen Kirkby,

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Nicholas J. Gross, MD,

Comparison of the characteristics at first enrolment for United Network for Organ Sharing (UNOS) patients (n=8315) and virtual patients (n=2 048 784).

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.

David P. Mason, MD, Jeevanantham Rajeswaran, MS, Sudish C

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p

Predicted values for a, b) FEV1, c, d) FVC and e, f) FEV1/FVC by sex and ethnic group. a, c, e) Males and b, d, f) females. Predicted values for a, b)

Response to two identical exercise tests (T1 and T2) in 278 adults and 95 children with signs and symptoms of asthma but no definite diagnosis. Response.

Lung volume variations during quiet breathing (grey lines) and vital capacity (blue lines) in an healthy subject (left) and a muscular dystrophy patient.

Effects of Extended Pleurectomy and Decortication on Quality of Life and Pulmonary Function in Patients With Malignant Pleural Mesothelioma David Burkholder,

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.

Supreme laryngeal mask airway for laparoscopic cholecystectomy in patient with severe pulmonary fibrosis M. Carron, A. Marchet, C. Ori British Journal.

Meta-analysis of the Effect of a Pulmonary Rehabilitation Program on Respiratory Muscle Strength in Patients with Chronic Obstructive Pulmonary Disease

Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.

Expanded version of the early part of a subject's volume–time spirogram, illustrating back-extrapolation through the steepest part of the curve, where.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Lung function before and after inhaled salbutamol in a 16-year-old male with hypo-γ-globulinaemia and immunoglobulin G subclass deficiency. Lung function.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

Nasal polyposis in lung transplant recipients with cystic fibrosis

Patient case study 2—fibrotic uILD in the setting of IPAF

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Forest plots of the correlation between high-resolution computed tomography (HRCT) scores and pulmonary function test values. Forest plots of the correlation.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

Dynamic Spirometry By Dr. Ola Mawlana.

Ribavirin in Desquamative Interstitial Pneumonia

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

E. Rand Sutherland, MD, MPH Journal of Allergy and Clinical Immunology

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Lung function adjusted for body length and gestational age in male and female premature infants. Lung function adjusted for body length and gestational.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Supplementary Fig.1. The flow of the subjects.

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

A) Dyspnoea response at rest, iso-time, and peak exercise in 20 patients with fibrotic interstitial lung disease during constant work-rate cycle exercise.

Interleukin (IL)-1β and IL-18 in stable chronic obstructive pulmonary disease (COPD) patients. a) IL-1β and IL-18 relative transcript levels in lung tissues.

Assessment of patients with possible occupational asthma.

Comparison of total lung capacity (TLC), slow vital capacity (SVC) and carbon monoxide transfer factor (Tlco) in patients with stable interstitial lung.

Presentation transcript:

Decline of lung function of a LTX patient who rapidly developed severe BOS at our centre. Decline of lung function of a LTX patient who rapidly developed severe BOS at our centre. Adjunctive treatment is initiated at time point 0. The loss of FEV1 slows after treatment. However, it is unclear if this represents the effect of treatment or a natural exponential decline of disease progression. FVC: forced vital capacity. David Abelson, and Allan R. Glanville Breathe 2018;14:278-287 ©2018 by European Respiratory Society